Denali TherapeuticsDNLI
DNLI
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
80% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $750K
38% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 60
27% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 33
3% more funds holding
Funds holding: 216 [Q3] → 222 (+6) [Q4]
0.46% more ownership
Funds ownership: 88.42% [Q3] → 88.88% (+0.46%) [Q4]
29% less capital invested
Capital invested by funds: $3.69B [Q3] → $2.61B (-$1.08B) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
97%
upside
Avg. target
$39
221%
upside
High target
$87
615%
upside
9 analyst ratings
9 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Tazeen Ahmad 26% 1-year accuracy 9 / 34 met price target | 130%upside $28 | Buy Maintained | 10 Mar 2025 |
Morgan Stanley Matthew Harrison 46% 1-year accuracy 11 / 24 met price target | 171%upside $33 | Overweight Assumed | 7 Mar 2025 |
B. Riley Securities Mayank Mamtani 10% 1-year accuracy 2 / 21 met price target | 188%upside $35 | Buy Reiterated | 5 Mar 2025 |
Oppenheimer Jay Olson 19% 1-year accuracy 17 / 89 met price target | 245%upside $42 | Outperform Maintained | 3 Mar 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 358 met price target | 615%upside $87 | Buy Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 3 articles about DNLI published over the past 30 days
Neutral
Market Watch
5 days ago
Biotech stocks have been hit hard. Why they're a great value now.
Biotech is one of the U.S. stock market's most unloved sectors. But several indicators suggest that a bottom in sentiment could be near, and that's normally a good time to buy.
Positive
Seeking Alpha
1 week ago
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson's Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact.
Positive
Zacks Investment Research
1 week ago
Why You Shouldn't Bet Against Denali (DNLI) Stock
Denali (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Neutral
Zacks Investment Research
1 month ago
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
Neutral
GlobeNewsWire
1 month ago
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights.
Positive
Zacks Investment Research
1 month ago
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational therapy, tividenofusp alfa.
Neutral
GlobeNewsWire
1 month ago
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These data, along with recent Breakthrough Therapy designation, further support the company's plan to submit a biologics license application (BLA) in early 2025 for accelerated approval and deliver this potential treatment to the Hunter syndrome community in late 2025 or early 2026. The Phase 1/2 results are being presented this week at the 21st Annual WORLDSymposium™ conference in San Diego, California.
Positive
Zacks Investment Research
2 months ago
Denali Gains 26.6% in a Year: How Should You Play the Stock?
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost.
Neutral
Benzinga
2 months ago
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
Denali Therapeutics Inc DNLI CEO Ryan Watts presented at the J.P. Morgan Healthcare Conference.
Negative
Seeking Alpha
2 months ago
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025.
Charts implemented using Lightweight Charts™